Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03652337 · ClinicalTrials.gov registry record · NA

Meibomian Gland Dysfunction Management

A NA study of Meibomian Gland Dysfunction and Contact Lens Discomfort, sponsored by University of the Incarnate Word.

Active
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT03652337 is a NA study of Meibomian Gland Dysfunction and Contact Lens Discomfort that is active but no longer recruiting, run by University of the Incarnate Word. The registered enrollment target is 60 participants, below the 95-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03652337, a NA study of Meibomian Gland Dysfunction and Contact Lens Discomfort, is active but no longer recruiting, sponsored by University of the Incarnate Word.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare electronic debridement of the eyelid margin (BlephEx) to manual debridement of the eyelid margin as treatment options for patients intolerant to contact lens wear consequent to Meibomian gland dysfunction.

Interventions

  • DEVICE BlephEx
  • DEVICE Manual debridement

Study Locations (1)

Texas

  • Rosenberg School of Optometry - San Antonio

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2018-05-10
Est. Completion 2019-04-10
Phase NA

Sponsor

University of the Incarnate Word

11 total trials

What the Registry Record Tells You About NCT03652337

The ClinicalTrials.gov registry entry for NCT03652337 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (37% lower). The listed sponsor is University of the Incarnate Word, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Meibomian Gland Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which BlephEx is the first listed.

NCT03652337 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03652337 about?

NCT03652337 is a clinical study titled "Meibomian Gland Dysfunction Management". The purpose of this study is to compare electronic debridement of the eyelid margin (BlephEx) to manual debridement of the eyelid margin as treatment options for patients intolerant to contact lens wear consequent to Meibomian gland dysfunction.

What is the current status of trial NCT03652337?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2018-05-10. Estimated completion is 2019-04-10.

What conditions does trial NCT03652337 study?

This clinical trial studies the following conditions: Meibomian Gland Dysfunction, Contact Lens Discomfort.

What interventions are being tested in trial NCT03652337?

The interventions under investigation include: BlephEx (DEVICE), Manual debridement (DEVICE).

Who is sponsoring clinical trial NCT03652337?

This trial is sponsored by University of the Incarnate Word, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03652337 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Meibomian Gland Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.